No results for ‘’
Ajanta Pharma Ltd
₹3563.60
(1.80%)
Sun, 27 Sept 2026, 03:03 pm
Health Technology
Pharmaceuticals: Major
24.5KAjanta Pharma Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 7.02 | 5.74 | 4.28 | 2.36 | 6.27 | 4.62 | 6.93 | 13.47 | 15.08 | 34.81 | 29.86 | 30.57 | 26.40 | 23.44 | 25.49 | 23.88 | 21.94 | 26.34 | 34.55 | 35.61 |
| Price to book ratio | 0.80 | 0.73 | 0.70 | 0.38 | 1.15 | 1.02 | 1.79 | 3.83 | 5.93 | 12.81 | 10.42 | 9.88 | 6.06 | 4 | 4.59 | 5.18 | 4.73 | 4.49 | 7.90 | 8.63 |
| Price to sales ratio | 0.38 | 0.33 | 0.30 | 0.17 | 0.52 | 0.46 | 0.80 | 1.64 | 2.99 | 7.42 | 7.24 | 8.09 | 6.01 | 4.50 | 4.65 | 5.49 | 4.74 | 4.16 | 6.74 | 7.10 |
| Price to cash flow ratio | 6.51 | 9.62 | 31.13 | 5.47 | 2.84 | 2.84 | 10.14 | 6.98 | 16.75 | 38.57 | 37.41 | 25.45 | 43.41 | 23.98 | 26.29 | 27.40 | 28.15 | 19.61 | 34.88 | 27.68 |
| Enterprise value | 179Cr | 193Cr | 262Cr | 302Cr | 426Cr | 410Cr | 723Cr | 1589Cr | 3541Cr | 10703Cr | 12374Cr | 15245Cr | 12100Cr | 8940Cr | 11725Cr | 15262Cr | 15330Cr | 14684Cr | 27776Cr | 32210Cr |
| Enterprise value to EBITDA ratio | 5.27 | 4.86 | 5.09 | 4.71 | 5.52 | 4.25 | 5.32 | 7.42 | 10.46 | 22.41 | 20.61 | 22.80 | 19.74 | 16.32 | 16.86 | 15.58 | 16.91 | 17.45 | 23.57 | 25.55 |
| Debt to equity ratio | 0.91 | 1.01 | 1.29 | 1.59 | 1.23 | 0.83 | 0.67 | 0.32 | 0.22 | 0.09 | 0.07 | 0 | 0 | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Return on equity % | 0 | 13.11 | 17.49 | 17.42 | 19.88 | 24.51 | 29.33 | 32.43 | 47.40 | 43.20 | 40.91 | 36.75 | 25.97 | 18.05 | 19.31 | 23.38 | 22.77 | 17.68 | 23.47 | 25.02 |
Ajanta Pharma Ltd Ratios
The Ajanta Pharma Ltd Ratios page provides a complete fundamental analysis of Ajanta Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Ajanta Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Ajanta Pharma Ltd (NSE: AJANTPHARM, BSE: 532331) is currently trading at ₹3563.60, with a market capitalization of ₹44562.26Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Ajanta Pharma Ltd remains a key stock for fundamental analysis using Ajanta Pharma Ltd Ratios.
Ajanta Pharma Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Ajanta Pharma Ltd P/E ratio currently stands at 35.61, making it one of the most tracked metrics in Ajanta Pharma Ltd Ratios.
Historically, the Ajanta Pharma Ltd P/E ratio has shown strong fluctuations:
- 2024: 35.61
- 2023: 34.55
- 2022: 26.34
- 2021: 21.94
- 2020: 23.88
The rising Ajanta Pharma Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Ajanta Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 8.63.
Historical P/B trend:
- 2024: 8.63
- 2023: 7.90
- 2022: 4.49
- 2021: 4.73
Ajanta Pharma Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Ajanta Pharma Ltd P/S ratio currently stands at 7.10, an important part of Ajanta Pharma Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 7.10
- 2023: 6.74
- 2022: 4.16
- 2021: 4.74
The rising Ajanta Pharma Ltd P/S ratio indicates improved revenue valuation by investors.
Ajanta Pharma Ltd Price to Cash Flow Ratio (P/CF)
The Ajanta Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 27.68.
Historical Ajanta Pharma Ltd Price to Cash Flow Ratio:
- 2024: 27.68
- 2023: 34.88
- 2022: 19.61
- 2021: 28.15
- 2020: 27.40
The declining Ajanta Pharma Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Ajanta Pharma Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Ajanta Pharma Ltd EV currently stands at ₹32210Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 32210Cr
- 2023: 27776Cr
- 2022: 14684Cr
- 2021: 15330Cr
Ajanta Pharma Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.
EV/EBITDA Ratio
The Ajanta Pharma Ltd EV/EBITDA ratio is currently 25.55, a key metric in Ajanta Pharma Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 25.55
- 2023: 23.57
- 2022: 17.45
- 2021: 16.91
Higher Ajanta Pharma Ltd EV/EBITDA suggests premium valuation.
Ajanta Pharma Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Ajanta Pharma Ltd D/E ratio is currently 0.01, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.01
- 2023: 0.01
- 2022: 0.01
- 2021: 0.01
Ajanta Pharma Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Ajanta Pharma Ltd ROE currently stands at 25.02%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 25.02
- 2023: 23.47
- 2022: 17.68
- 2021: 22.77
Ajanta Pharma Ltd demonstrates strong profitability and efficient capital utilization.
Ajanta Pharma Ltd Ratios Analysis Summary
The Ajanta Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Ajanta Pharma Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Ajanta Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.